Radalbuvir

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Radalbuvir
Radalbuvir.svg
Clinical data
Synonyms GS-9669
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
Formula C30H41NO6S
Molar mass 543.72 g·mol−1
3D model (JSmol)

Radalbuvir (INN,[1] also known as GS-9669) is an experimental antiviral drug for the treatment of hepatitis C virus (HCV) infection developed by Gilead Sciences. Radalbuvir acts as an NS5B inhibitor. It is currently in clinical trials.[2]

References[edit]

  1. ^ "International Nonproprietary Names for Pharmaceutical Substances" (PDF). WHO Drug Information. 28 (4). 2014. 
  2. ^ "Search of: GS-9669 — List Results". ClinicalTrials.gov.